Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides presented on the cell surface of cells in the MHC class I (MHC I) context in which the invariant chain has been engineered to favor loading of specific antigens and generate CD8+ T-cell activation

Abstract: The invention relates to compositions, methods and therapies for the treatment of inflammation caused by infection with Propionibacterium acnes. The compositions include a combination of peptide and anti-TNF. The peptide consists of a specific amino acid sequence or a peptide consisting of an amino acid sequence derived the specific amino acid sequence by deletion, substitution, insertion or addition of one or more amino acids. The administration of the peptide and anti-TNF in therapeutically effective amounts to a patient is effective to suppress, by immune response, inflammation caused by infection with Propionibacterium acnes.

Abstract: Described herein are compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation, regulated expression of one or more antigens of interest, and/or N-glycan modification of secreted/surface antigens.

Abstract: The disclosure relates to attenuated bacterial cells expressing glycans and glycoconjugate antigens and their use in the manufacture of whole cell vaccines effective at preventing or treating bacterial infections in non-human species.

Abstract: The invention is directed to an oral vaccine composed of a micronized freeze-dried rotavirus particle suspension with buffering excipients in a non-aqueous liquid. This IVT-06 formulation has imparted heat stability by protecting the virus at temperatures of 30° C. and 40° C. for at least twelve months. Extrapolations from the 12-month stability data indicate a shelf life of more than two years at 30° C., and six months at 50° C. In addition, for ease of administration, the formulated dose has a volume of 0.5 mL.

Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.

Abstract: The present invention provides novel nanoparticle presented vaccine compositions that are stabilized with a locking domain. Various immunogens can be employed in the preparation of the vaccine compositions, including viral immunogens such as HIV-1 and Ebola viral immunogens, and non-viral immunogens such as immunogens derived from bacteria, parasites and mammalian species. The invention also provides methods of using such vaccine compositions in various therapeutic applications, e.g., for preventing or treating viral infections.

Abstract: The present invention relates to a composition for raising an immune response in animal which decreases the risk of chikungunya and smallpox infection, Zika virus and smallpox infection, and/or chikungunya, Zika virus and smallpox infection. The composition comprises a pharmaceutically acceptable carrier and an attenuated poxvirus, wherein the poxvirus genome comprises a nucleic acid sequence encoding the 26S subgenomic polyprotein of chikungunya virus and/or the PrME of Zika virus.

Abstract: Methods of vaccination of animals are provided. In an embodiment, a paired administration of a primer vaccine provides for non-oral administration of a vaccine and an oral administration of the vaccine and can be followed by a paired administration of a booster vaccine of a non-oral administration and an oral administration. Embodiments provide the non-oral and oral administration are within three days of each other. The methods provide for improved protective response in an animal compared to administration of a primer non-oral administered vaccine followed by three booster non-oral administered vaccines. An adjuvant is provided that is a microcrystalline polysaccharide-based adjuvant derived from delta inulin.

Abstract: The invention provides combinations of derivatives of decitabine and other active agents, including T-cell activating agents, cancer vaccines, and adjuvants. Some derivatives of decitabine exhibit superior chemical stability and shelf life, with similar physiological activity. Methods of treating one or more myelodysplasia syndromes, cancers, haematological disorders, or diseases associated with abnormal haemoglobin synthesis using the combinations are described.

Abstract: Materials and methods for treating cholangiopathies by targeting TGR5, including materials and methods for treating cholangiopathies such as polycystic liver disease, are provided herein.

Abstract: A method of using a compound in a phototherapy procedure includes administering to a subject in need of treatment a therapeutically effective amount of a thio-substituted nucleobase, nucleoside, nucleotide, and/or analogs thereof; and exposing the administered compound to electromagnetic radiation.

Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Abstract: This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions.

Abstract: The present invention is directed to novel lyophilized pharmaceutical preparations comprising a cytotoxic dipeptides such as melphalan flufenamide and one or more excipient(s) selected from the group comprising a polysorbate; a polyethylene glycol; ?-cyclodextrin; ocyclodextrin; hydroxypropyl-?-cyclodextrin; sulfobutylether-?-cyclodextrin; lactose; benzyl alcohol; disodium succinate; propylene glycol; Cremophor EL; Dimethyl sulfoxide; D-mannitol; Trehalose; Sucrose and an amino acid. This preparation may be further formulated and is useful in cancer therapy.

Abstract: This invention relates to the field of topical treatments for infections such as nail infections, particularly fungal infections of the nail commonly referred to as onychomycosis. Particularly, the invention relates to novel compositions containing peroxide for the treatment of such nail infections and other infections.

Abstract: Pharmaceutical formulations containing lipoic acid derivatives and ion pairs thereof are described. The pharmaceutical formulations are useful in the treatment of medical disorders, such as cancer.

Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum based chemotherapeutics.

Abstract: Provided herein are polymers of Formula (I), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, and isotopically labeled derivatives thereof, compositions, and formulations thereof. The polymers described herein are biocompatible, non-toxic, water compatible, and operationally simple to formulate. Also provided are methods and kits involving the polymers described herein (e.g., methods of using polymers described herein for delivering agents (e.g., for therapeutic, diagnostic, prophylactic, imaging, ophthalmic, intraoperative, or cosmetic use) to a subject, cell, tissue, or biological sample, as part of materials (e.g., biodegradable materials, biocompatible materials, wound dressing (e.g., bandages), drug depots, coatings), or as scaffolds for tissue engineering. Provided are methods for synthesizing the polymers described herein, and polymers described herein synthesized by the synthetic methods described herein.

Abstract: Aspects of the present invention are directed to compositions that are useful for delivery of an active ingredient to a subject. Some embodiments are formulated with an active ingredient, including, for example, a non-steroidal anti-inflammatory drug (NSAID), such as aspirin, ibuprofen, ketoprofen, or naproxen, acetaminophen, or a polypeptide or protein, such as insulin, wherein the active ingredient is stabilized and greater than 90% of the particles of the active ingredient have a particle size that is less than or equal to or any number in between 100, 90, 80, 70, 60, 50, 40, 30, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, or 4 nanometers, or smaller, as determined by Dynamic Light Scattering (DLS), using a volume-weighted particle size distribution calculation method.

Abstract: The present disclosure relates to the field of pharmaceutical chemistry, and particularly to a compound represented by Formula (I), a preparation method and medical use thereof. In the compound represented by Formula (I), a lactulosyl group is connected to a heteroatom of genin (G) via a glycosidic bond, wherein the genin (G) is a group formed by removing one hydrogen atom from a heteroatom of an active pharmaceutical molecule, and “” indicates that the lactulosyl group is connected to the heteroatom of the genin (G) via an ?-glycosidic bond or a ?-glycosidic bond. Pharmacokinetic experiments prove that the lactuloside compound according to the present disclosure can pass through the gastrointestinal tract of a mammal without being absorbed significantly by the gastrointestinal tract and hydrolyzed significantly by endogenous enzymes of a mammal host. Therefore, the lactuloside compound can arrive at the colon site of the mammal, and release an active drug in the colon under the action of colon flora.

Abstract: Methods are provided for transfecting cells with large cargo using a poly(beta-amino ester) (PBAE) molecule, and achieving high efficiency and viability. A method is provided of transfecting cells with a cargo, by forming a complex of the cargo with a (PBAE) molecule, mixing the complex with a first buffer and contacting the complex with the cells, wherein the cargo has a dimension of at least 0.1 ?m. The PBAE molecule may be formed by reacting an amine with a di(acrylate ester). In some aspects, the PBAE molecule is poly(1,4-butanediol diacrylate-co-4-amino-1-butanol). In some aspects, the PBAE molecule is capped with 1-(3-aminopropyl)-4-methylpiperazine.

Abstract: The invention provides for preparing a polymer-active agent conjugate, the method comprising the steps of reacting an amino acid derivative with a biologically active agent under conditions to form a polymer-active agent conjugate.

Abstract: This document relates to conjugates of TNF inhibitors or derivatives thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.

Abstract: Targeted constructs and pharmaceutical formulations thereof, comprising at least one conjugate of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via an optional internal linker moiety have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the targeted constructs and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.

Abstract: Provided herein are conjugated immunoglobulins and methods for generating conjugated immunoglobulins using a microbial transglutaminase.

Abstract: In one aspect, the disclosure provides mesoporous silica nanoparticles (MSNPs), monodisperse populations of MSNPs and related protocells which exhibit cell binding specificity. For example, MSNPs and protocells of the disclosure may be used to target specific delivery of therapeutic agents to CD19 or EGFR expressing cancer cells, or target specific delivery of therapeutic agents to other cell types. Related protocells, pharmaceutical compositions and therapeutic and diagnostic methods are also provided.

Abstract: This disclosure provides therapeutic compositions and methods for treating multiple sclerosis or a multiple sclerosis-related disorder in a subject in need thereof comprising administering an effective amount of an antigen-MHC-nanoparticle complex to the subject, wherein the antigen is a multiple sclerosis-related antigen.

Abstract: In vivo gene therapies for immune deficiencies are described. The in vivo gene therapies utilize a foamy viral vector including a PGK promoter with a therapeutic gene. The foamy viral vector can be beneficially administered with cell mobilization into the peripheral blood.

Abstract: The present disclosure provides methods of treating a disease or delivering a therapeutic agent to a mammal comprising administering to the mammal's cisterna magna and/or ventricle an rAAV particle containing a vector comprising a nucleic acid encoding a therapeutic protein inserted between a pair of AAV inverted terminal repeats in a manner such that cells with access to the cerebrospinal fluid (CSF) express the therapeutic agent and in certain embodiments secretes the therapeutic agent into the CSF for distribution to the brain.

Abstract: Provided are nucleic acid-based expression constructs for the targeted production of a therapeutic protein within a cell that is associated with aging, disease, another condition. Also provided are vectors and systems for the delivery of those nucleic acid-based expression constructs as well as methods for using such nucleic acid-based expression constructs, vectors, and systems for reducing, preventing, and/or eliminating the growth and/or survival of an age-, disease-, or condition-associated cell and for the treatment of a disease or condition that is associated with an age, disease, or condition associated cell.

Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×108 infectious viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor.

Abstract: The present invention relates to an ophthalmic solution of lissamine green which has shown to be particularly stable over time and well tolerated by the eye. Therefore, the ophthalmic solution finds advantageous application in the diagnosis of corneal and conjunctival anomalies.

Abstract: A composition for imaging a cell includes a first imaging probe and a second imaging probe that include respectively a first reporter moiety and a second reporter moiety. The first reporter moiety and the second reporter moiety form a signaling complex that produces a detectable signal when the first imaging probe and second imaging probe complex with first and second biomarkers of the cell.

Abstract: Provided are photoacoustic imaging contrast agents that include at least one radiation-absorbing component comprising a bacteriochlorin, a metallobacteriochlorin, a derivative thereof, or a combination thereof. Also provided are methods for using the disclosed photoacoustic imaging contrast agents either singly or in combination for generating an image of a volume, optionally a subject or a body part, cell, tissue, or organ thereof. Further provided are compositions and methods for multiplex photoacoustic imaging of a volume, optionally a subject or a body part, cell, tissue, or organ thereof using photoacoustic imaging contrast agents that include a plurality of the presently disclosed bacteriochlorins, metallobacteriochlorins, and/or derivatives thereof simultaneously.

Abstract: There is provided a labeling precursor compound represented by the general formula (2): wherein S represents a substrate, L represents a straight alkyl group having 1 to 6 carbon atoms which may contain an ether group, R1 and R2 each independently represent a straight or branched alkyl group having 1 to 30 carbon atoms, or a substituted or unsubstituted monocyclic or condensed polycyclic aryl group, R3 each independently represent an alkyl group having 1 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms, and p represents an integer of 0 to 4.

Abstract: A method for preparing 18F radiolabeled biomolecules and agents for 18F-PET imaging is disclosed herein. A perfluoroaryl-conjugated target tracer is synthesized and purified with temperature and solvent conditions that are mild for the tracer molecule. The purified perfluoroaryl-conjugated target tracer is then labeled with 18F using 18F salts within a short reaction time, and with temperature and solvent conditions that are mild for the tracer molecule. The method provides a quick and convenient process that maintains the biological activities of the target molecules. The radio-labeled biomolecules may be used as contrast agents for Positron Emission Tomography (PET).

Abstract: The present invention relates to a pigment-coupled mannosyl serum albumin complex and a lymph node-probing composition comprising the same. More particularly, when administered to mice, a pigment-coupled mannosyl serum albumin complex can be observed with the naked eye to exist in a condense state for a long period of time in the inguinal lymph node. Thus, the complex and a composition comprising the same can be useful for probing lymph nodes.

Abstract: The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.

Abstract: The invention relates generally to methods of using a thiol-Michael addition hydrogel for providing intracavitary brachytherapy and/or displacing tissue and organs. The thiol-Michael addition hydrogel may be used as a packing material and an attenuation material for intracavitary brachytherapy applications. The invention also relates generally to a brachytherapy applicator, which may be used in conjunction with the thiol-Michael addition hydrogel and methods thereof. The invention also relates to a kit comprising at least one container containing the precursor materials of the thiol-Michael addition hydrogel.

Abstract: A method for producing a sterilized oxygen-absorbing multilayer body is provided. The method may include: irradiating with radiation an oxygen-absorbing multilayer body comprising at least an oxygen-absorbing layer containing a transition metal catalyst and a thermoplastic resin (a) having a tetralin ring as a structural unit and a layer containing a thermoplastic resin (b); and heating the oxygen-absorbing multilayer body which has been irradiated with radiation in the sterilizing step at a temperature of the glass transition temperature of the thermoplastic resin (a) minus 20° C. or more and lower than the glass transition temperature of the thermoplastic resin (a) for 50 hours or more.

Abstract: Methods and apparatus are provided for ultraviolet (UV) fluid purification, wherein the fluid is in a gaseous, liquid or solid form or combination thereof, comprising UV-C LED modules having improved light extraction efficiency. UV-C LED(s) are in optical communication with one or more UV-C transmissive window elements.

Abstract: A building automation system (BAS) may control ultra-violet (UV) lights to intelligently disinfect a disinfection environment (e.g., a patient room). In some examples, the BAS includes a disinfection environment tracking engine and a UV light control engine. The disinfection environment tracking engine may access patient room data indicative of a state of a patient room of a patient, medical data of the patient, the medical data of the patient specifying a medical condition of the patient, real-time location data of the patient. The UV light control engine may control operation of UV lights to disinfect the patient room based on the patient room data, the medical data of the patient, and the real-time location data of the patient.

Abstract: An odor control agent comprising: a filler; a binder; an active comprising an aminopolycarboxylic acid and a polyprotic acid. An odor control agent comprising: an active comprising an aminopolycarboxylic acid and a polyprotic acid, wherein at least one of the aminopolycarboxylic acid or the polyprotic acid is the salt form of the acid.

Abstract: This invention relates in general to a device, which uses the heat from a light bulb to dispense fragrance oil. Its modern design makes it work as a functional home decor, too. It works as both a light and a warmer aid, so you get real value for what you pay for. Its color works well with any warmer color, too, making it among the most versatile of all.

Abstract: The present invention discloses a system for deodorizing an environment comprising a fan disposed within a housing. The fan creates an air stream by pulling air through an intake and expelling air through an exhaust. An ozone generator is disposed within the housing. As air is moved past the ozone generator, oxygen in the air is converted to ozone and expelled through the exhaust to deodorize the surrounding environment.

Abstract: Provided is a fragrance discharge apparatus. The fragrance discharge apparatus includes one or more fragrance cartridges configured to store a fragrance material; a body to which the fragrance cartridge is mounted; a controller provided in the body to control the discharge of the fragrance material; and a fan configured to mix air and the fragrance material discharged from the fragrance cartridge and make the mixed air flow to the outside of the body.

Abstract: An accurately mixed fragrance can be provided. A fragrance generation device includes: a first ultrasonic vibrator provided in a water container that contains water and used for atomizing the water; a first emission hole used for emitting the water atomized by the first ultrasonic vibrator; a plurality of second ultrasonic vibrators provided in a plurality of perfume containers that individually contain multiple types of perfumes, respectively, and used for atomizing the perfumes; a plurality of second emission holes arranged around the first emission hole and used for emitting the perfumes atomized by the plurality of second ultrasonic vibrators; and a control unit configured to control driving of the first ultrasonic vibrator and the second ultrasonic vibrators.

Abstract: A lighting fixture includes a first compartment including a light sealed air plenum and a first lighting source arranged in the plenum to irradiate passing air through the plenum to destroy pathogens. A second compartment is configured to be external to the first compartment. A second lighting source is arranged in the second compartment to illuminate an area adjacent to the second compartment.